Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.


Icahn School of Medicine at Mount Sinai, New York, NY, USA. [Email]


Persistence rates over 36 months with denosumab in patients diagnosed with osteoporosis in a real-world setting were examined, along with baseline patient characteristics predictive of persistence. This study represents the longest observational period with denosumab persistence and shows higher persistence rates when compared to bisphosphonates.


Denosumab,Osteoporosis,Persistence,Real-world data,Treatment,